Royal Bank of Canada
NGEN

Royal Bank of Canada’s NervGen Pharma NGEN Stock Holding History

Royal Bank of Canada’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Buy
+171,961
New +$745K ﹤0.01% 3928

Other funds holding NGEN

PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
VFIC
Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Royal Bank of Canada's NGEN Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in NervGen Pharma (NGEN) in Q1 2026: 171,961 shares worth $648K. The stake represents ﹤0.01% of the portfolio and ranks #3928 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

  • Royal Bank of Canada held 171,961 shares of NervGen Pharma worth $648K as of Q1 2026.
  • NervGen Pharma was a new Royal Bank of Canada position in Q1 2026.
  • NervGen Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3928 holding.
  • 45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.